Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. , Am J Obstet Gynecol.: 2025
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. , Nature Communications: 2025
Smith AJ, Pancoe S, Lynch MP, Wachlin M, Powell K, Hinkle SN, Koelper NC, Doherty M, Bekelman JE, Simpkins F, Ko EM Rideshare services for transportation assistance in gynecologic oncology: a quality improvement study , BMC Health Serv Res: 2025
Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, Rames MJ, Kim S, Guo X, Jameson N, de Jong PR, Yea S, Harford L, Li J, Mathews CA, Doroshow DB, Charles VJ, Kim D, Fischer K, Samatar AA, Jubb A, Bunker KD, Blackwell K, Simpkins F, Meric-Bernstam F, Mills GB, Harismendy O, Ma J, Lackner MR Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers , NPJ Precis Oncol: 2025
Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Taylor RN, Barnicle A, Munley JY, Aghajanian C Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis , Cancer: 2025
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. , J Nucl Med: 2025
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib , Genome Med: 2024
Boland MR, Tubridy E, Solorzano SS, Simpkins F, Smith AJB, Ko EM Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US. , JAMA Netw Open: 2024
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F. Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer. , under review Nature Communications: 2024,27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1.
Fiona Simpkins, Dimitrios Nasioudis, Stephanie L. Wethington, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Drew A. Torigian, Dalia K. Omran, Diego Rodriguez, Simon Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Geoffrey Shapiro, Stephanie Gaillard, Robert L. Giuntoli II, Joyce F. Liu Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (Cohort A). , ASCO presentation (ASCO Anual Meeting, June, 2024, Chicago, USA:
JCO Abstracts, June, 2024: 2024
